Medium is based on the Centers for Disease Control
recommended formulation
SANTA
MARIA, Calif., July 15,
2024 /PRNewswire/ -- Hardy Diagnostics is pleased to
announce its latest product release in the battle to detect and
identify Candida auris from skin and environmental
samples. The medium is based on the Centers for Disease Control
(CDC) formulation for Sabouraud Salt Dulcitol (SSD) Broth with
chloramphenicol and gentamicin.
About Candida auris
Candida auris is an evolving fungal
healthcare-associated pathogen that represents a serious multi-drug
resistant (MDR) global threat. Though the organism often presents
fewer virulence factors than Candida albicans, C.
auris may persistently colonize the skin and hospital
environment, making its transmission within and between healthcare
settings more difficult to control¹,².
C. auris fungemia results in a wide range of
mortality rates (from 32%-66%), depending upon the patient's
overall condition, underlying disease, geographic region, access to
medical care, and age³. A review of the organism's genome
demonstrates it harbors genes well-characterized as virulence
factors in other Candida species, as well as genes
for biofilm production and MDR transcription factors³.
Auris Enrichment Broth
Hardy Diagnostics' Auris Enrichment Broth is based on
the CDC formulation for Sabouraud Salt Dulcitol (SSD) Broth
with Chloramphenicol and Gentamicin, as outlined by Welsh et al.⁴.
The medium, sometimes referred to as Salt SAB Broth, maintains a
lower pH to encourage the growth of fungal isolates. The broth
contains dulcitol as the sole carbon source, and chloramphenicol
and gentamicin as selective agents against unwanted bacterial
growth. Peptones provide nitrogen and amino acids.
The CDC protocol recommends this broth for surveillance
of C. auris from skin swabs and environmental samples⁵.
Positive broth samples may be subcultured to chromogenic media,
such as HardyCHROM™ Candida + auris (Cat. no. G343), for
further identification. Suspect colonies with a teal-to-teal-green
"bullseye" center will fluoresce on this chromogenic medium and can
be confirmed on the MALDI-TOF.
Environmental Persistence and Disinfection
C. auris may persist on environmental surfaces in
healthcare settings and has been cultured from multiple locations
in patient rooms. The organism exhibits some degree of tolerance to
disinfectants, allowing it to survive on surfaces for greater than
three weeks⁶. It can be found on high-touch surfaces near the
patient's bedside, such as tables, rails, and carts; mobile or
reusable equipment shared between patients such as blood pressure
cuffs, glucometers, temperature probes, and ultrasound machines;
and even on surfaces further away from the bedside such as
windowsills⁵.
Environmental disinfection procedures should include routine
cleaning and disinfection of patient rooms, as well as mobile and
reusable equipment. Fungicidal disinfectants should be used
following the manufacturer's directions. Environmental sampling may
be useful in instances of outbreak investigations, surveillance, or
to determine the reservoirs of ongoing transmission.
Find more information on Auris Enrichment Broth here.
ABOUT HARDY DIAGNOSTICS
Hardy Diagnostics is an FDA-licensed manufacturer of medical
devices for microbiological testing with an ISO 13485 certified
Quality Management System. Hardy Diagnostics manufactures 2,700
products, distributes more than 13,000 products, offers
services to more than 10,000 laboratories, exports products to over
80 foreign distributors, and maintains a network of nine
distribution centers throughout the
United States. Hardy Diagnostics supports the microbiology
needs of clinical, pharmaceutical, cosmetics and personal care, as
well as the food and beverage industries. The company is 100% owned
by the employees who work there. Serving laboratory scientists
since 1980, Hardy Diagnostics' mission is to "produce and
distribute the finest products for the detection of microorganisms
and partner with its laboratory customers to diagnose and prevent
disease."
References
- Anderson, N.L., et al. Cumitech 3B; Quality Systems in the Clinical Microbiology
Laboratory, Coordinating ed., A.S. Weissfeld. American Society for
Microbiology, Washington,
D.C.
- Isenberg, H.D. Clinical Microbiology Procedures Handbook, Vol.
I, II & III. American Society for Microbiology, Washington, D.C.
- Rossato, L. and A.L. Colombo.
2018. Candida auris: What Have We Learned About its Mechanisms of
Pathogenicity? Frontiers in Micro.
- Welsh RM, Bentz ML, Shams A, Houston H, Lyons A, Rose LJ,
Litvintseva AP. 2017. Survival, persistence, and isolation of the
emerging multi-drug resistant pathogenic yeast Candida auris on a
plastic healthcare surface. J Clin Microbiol 55:2996–3005.
- The Centers for Disease Control and Prevention (CDC). Screening
for Candida auris colonization in healthcare settings: CDC
Screening
- Dire O., A. Ahmad, S. Duze, M. Patel. Survival of Candida
auris on environmental surface materials and low-level resistance
to disinfectant. 2023. J. Hosp. Infect. 137:17-23.
Contact:
|
(Megan
Maloney Roesner)
|
|
(805) 346-2766 x.
(5845)
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/hardy-diagnostics-releases-enrichment-broth-for-candida-auris-detection-302196247.html
SOURCE Hardy Diagnostics